Latin America and the Caribbean vs Russia: Percentage of bloodstream infection due to Escherichia coli resistant
Latin America and the Caribbean
30.9%
in 2022
Russia
58.5%
in 2021
Latin America and the Caribbean rank
13th
Russia rank
13th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Latin America and the Caribbean
- Russia
How they compare
Russia currently reports 58.5% against 30.9% in Latin America and the Caribbean, a difference of 27.6%.
That makes Russia's figure about 1.9 times Latin America and the Caribbean's.
Across all 5 years both countries report, Russia has been ahead every year.
Latin America and the Caribbean ranks 13th and Russia ranks 13th of 16 groups.
Russia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Latin America and the Caribbean | Russia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 20.2% | 66.0% | 45.8% | Russia |
| 2020s | 27.0% | 65.8% | 38.8% | Russia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Latin America and the Caribbean or Russia?
- Russia, at 58.5% against 30.9% in Latin America and the Caribbean as of 2021.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Latin America and the Caribbean and Russia?
- 27.6%, with Russia ahead.
- How many years of comparable data are there for Latin America and the Caribbean and Russia?
- 5 years are reported by both, from 2017 to 2021.
- How do Latin America and the Caribbean and Russia rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Latin America and the Caribbean ranks 13th and Russia ranks 13th of 16 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.